ProCE Banner Activity

Pivotal Phase II Trial of Valemetostat, an EZH1/EZH2 Inhibitor, in Patients With R/R Adult T-Cell Leukemia/Lymphoma

Slideset Download
Conference Coverage
Valemetostat yielded an ORR of 48% in patients with R/R ATL, most of whom had received prior treatment with mogamulizumab.

Released: December 14, 2021

Expiration: December 13, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation